COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patients…” by IBM

•

1 like•314 views

Create a system to track the temperature of vaccine using Smart IoT Edge devices, Smart IoT cloud Eco Systems, Blockchain and Smart Analytics from manufacturing to storage to transport to consumption – Reduce Wastage and Improve distribution and lower Inventory!

Technology

COLDCHAIN
SUNNY SINGH – ORIGINATOR/ FOUNDER - COLDCHAIN.IO
PETER CHANG
BHARAT CHATURVEDI
SAMEER BHARDWAJ
“Bringing high-quality vaccines and refrigerated medicine to patients…”

VACCINE FOR CHILDREN (VFC)
• CDC administers over $3 billion of vaccine to low-socioeconomic families
through Vaccines for Children (VFC) program each year
• Storage temperature control is vital to maintaining vaccine potency
• A meta-analysis published in Vaccine estimated 14 to 35% of delivered
vaccines are subjected to inappropriate storage temperatures
- Joint Study by NIST and CDC

A GLOBAL PROBLEM...!!!
• Vaccines Market :
2013: US – 10 B USD
2013: World – 23 B USD
2025: World ~100 B USD
• 20~40% of vaccination ineffective
due to poor temperature control…!!!
• 2-8˚C
•  DTP, Hep A, B, HPV, Influenza,
Meningococal, MMR, polio
• <-15˚C
•  Varicella, Zoster
Major Manufacturers:
• AlphaVax, Inc, Bavarian Nordic A/S
• Baxter Healthcare, Bharat Biotech
• Crucell /Johnson & Johnson
• Emergent biosolutions,
GlaxoSmithKline
• Medimmune, Merck & Co. Inc
• Novartis, Sanofi Pasteur
• Pfizer

SOLUTION
• Create a system to track the temperature of vaccine using Smart IoT Edge
devices, Smart IoT cloud Eco Systems, Blockchain and Smart Analytics from
manufacturing to storage to transport to consumption – Reduce Wastage and
Improve distribution and lower Inventory!

Coldchain
Applications/
API/ SDK
Coldchain
Smart Edge
Devices/
Sensors
Proof Of Concept (PoC TODAY!)
(using IBM Bluemix/ Hyperleger)
ccInventory
ccWatch
Persistence
Layer
•  getLastReading(d_id)
•  getReadings(d_id, start,
end)
•  getExceptions(d_id)
•  getExceptions(d_id, start,
end)
•  getDevices(l_id)
Service API
Coldchain.io
Coldchain
Smart IoT
API/ SDK
IoT
Watson
ATT IoT
Wind
River/
Helix
AWS
ccDistro
ccSDK
ccConsole

“Bringing high-quality vaccine and medicine to patients…”
COLD CHAIN

COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patients…” by IBM

Watch the presentation of this webinar here: https://bit.ly/3jmLYHu State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed. The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform. In this webinar, you will learn: • Benefits of platform technologies in vaccine development • Key considerations when deciding between platforms • Vaccine pipeline analysis and selected case studies Presented by: David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy

Viruses and vaccine production

Institute of chemical Technology, Mumbai

Industrial manufacturing of vaccines

Boon Keat Ngan

Ways Forward – Vaccine Manufacturing Tomorrow

Merck Life Sciences

In this webinar, you will learn: Trends in vaccine manufacturing Innovative solutions in facility design Case studies and proposals for future vaccine factories Considerations while setting up Quality Management Systems (QMSs) How validation helps accelerate regulatory approval Detailed description: How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities? The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.

Webinar: Re-imagining vaccine manufacturing to address global health challenges

MilliporeSigma

Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines

Merck Life Sciences

To date, manufacturing of lentivirus (LV) vectors for gene therapy commonly relies on transient transfection of adherent HEK293 cells. This method is costly, time-consuming, difficult to scale-up and poorly reproducible, rendering large-scale applicability to fulfill increasing demand of LV in clinical pipelines cumbersome. The use of suspension-adapted transient producer cell lines for LV production has overcome some of these challenges. Furthermore, successful creation of stable producer cell lines would allow creation of master and working cell banks easily amenable to commercial production. The ideal producer cell lines should demonstrate stability in growth and gene expression, and be easily adaptable to chemically defined culture conditions and optimized for high-titer virus production. The availability of more robust producer cell lines thus represents an important scalable first step towards manufacturing processes that are conducive to large-scale production. Ultimately, these producer cell lines must be screened to satisfy various biosafety and regulatory implications. In this webinar, you will learn: • Process development for transient and stable producer cell lines • Screening of cellular gene targets via CRISPR to improve LV production from producer cell lines • cGMP and Regulatory readiness: Cell line characterization and release testing through BioReliance® global service offering

Biosafety Testing Solutions for Cell & Gene Therapy

Merck Life Sciences

Abstract: Cell and gene therapies, well recognized as the drug revolution for this decade, are booming in Asian countries. Several cell and gene therapeutic products launched successfully in Europe and the US. The commercialization of these therapies is a hot topic, while ensuring product safety, especially quality for the new modalities, raises challenges within the industry. As a globally leading biosafety testing provider, Merck is committed to optimizing and advancing innovation and development of biosafety testing. As your reliable partner in CMC consideration, our comprehensive solutions for cell and gene therapy biosafety testing enable regulatory compliance. This presentation will cover rationale and methodologies for cell and gene therapy product testing from Merck’s BioReliance® testing portfolio, as well as provide an overview of our testing capabilities and services.

Ebola vaccine market analysis

Dimitrios Gouglas

Large-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing Microcarriers

Technovax Presentation @ Influenza Congress USA 2012

Hector Munoz

Virus Safety in Vaccine Production

Dr. Priyabrata Pattnaik

Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...

Merck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3ryE5ST Optimize your mesenchymal stem cell growth. Join our webinar to learn more about our GMP-compliant xeno free media formulation that supports high performance expansions and compatibility with scalable xeno free manufacturing conditions. Optimizing ex vivo cell expansion processes in preparation for clinical use is a critical step in cell therapy manufacturing. Given the curative and lifesaving impacts these therapies can have on patients, overcoming roadblocks with scalability and supply chain, using high quality raw materials are essential for therapeutic access. The GMP-compliant Stemline® XF MSC Medium and cocktail promotes expansion of human mesenchymal stromal/stem cells (hMSCs) to high densities while maintaining cell identity and quality. This product was designed for derivation and expansion of MSCs using xeno free conditions in planar and microcarrier-based culture platforms, easing the transfer between research, clinical, and manufacturing scale cultures. In this webinar, you will: • Explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells • Discover ways to derive MSC's from Bone Marrow in Xeno Free conditions from static to microcarrier-based suspension culture platforms. • Learn how Stemline® XF MSC Media provides robust performance and reduces scalability roadblocks Presented by: Kathleen Ongena, Ph.D., Head of Customer Applications and Mark Ventresco, Cell Therapy Product Manager

Emerging Viral Risks and Mitigation Strategies in Biologics Manufacturing

MilliporeSigma

Emerging viruses represent a constant challenge to biopharmaceutical manufacturers, and therefore formal risk assessments and informed programs of safety testing are necessary to assure safety. Emerging viruses such as the Zika virus have the potential to contaminate raw materials of human origin, Schmallenberg virus is a contaminant of bovine serum, and the long-known, but often ignored, Hepatitis E virus represents further challenges to the safety of raw materials. Results of in vitro culture and molecular testing strategies of raw materials for viruses with diverse characteristics will be presented, and holistic approaches to mitigate the risk of novel viruses to the safety of raw materials will be outlined. In this webinar, you will learn: -The identity of emerging viruses and potential impact on the safety of raw materials and final products -Testing strategies for specific viruses -Holistic approaches to mitigate the risk of novel viruses in raw materials

Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...

Merck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3icKkbZ Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays. Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors. This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50. In this webinar, you will learn: • Critical biosafety considerations for AAV vectors based on the latest regulatory guidance • How replication competent AAV testing fits into your bulk and final release testing package • The benefits of routine and platform assays over custom assay development Presented by: Steven McDade, Senior Technical Specialist, Field Technology Management Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services

Setting up for successful lot release testing by Edmund Ang

MilliporeSigma

Is your lot release testing strategy ready for global commercialization? In this webinar, you will learn: • CMC testing requirements with CHO production platform for global commercialization • Lot release testing of product intermediates and final product • Product-specific qualification study • Alternative rapid testing methods to advance lot release testing CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines. In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.

Does your cell line have a secret? Avoid surprises with characterization

Merck Life Sciences

Watch the recording of this webinar here: https://bit.ly/2Y05bV4 The first step to avoiding an unpleasant and costly contamination event is characterization of your cell banks. Regardless of the biotech product, careful characterization of the cell banks used in its production is the first step in mitigating the risk of a contamination event. In fact, cell line characterization is an important component of the overall viral safety strategy for the product. We will describe the testing necessary to ensure cell banks are free from infectious and other adverse agents and that meets current regulatory expectations. Different levels of testing are performed for master, working, and end of production cell banks, and the differences in testing for each of these types of banks will be discussed. In this webinar, you will learn: • The types of tests that are needed to fully characterize your cell banks • The best tests to use for your particular cell line • Reasons why a viral contaminant may be missed

Sartorius Solutions for Cell & Gene based Therapies

Raymond Goyco, III

Sartorius is a well respected global solution provider within the biologics industry, especially for antibody and vaccine production. Our proven products and services are being diversified for upstream and downstream processing of cells and viruses for allogeneic and autologous advanced therapies. Sartorius provides the cellular immunotherapy industry with a range of scalable single-use production technologies. Our portfolio supports viral vector transduction, cell expansion, and downstream processing steps including harvest, wash, and concentration of cells

Production and purification of Viral vectors for gene and cell therapy appli...

Dr. Priyabrata Pattnaik

Developing a single use adenovirus-vectored vaccine process through public-pr...

Merck Life Sciences

This work highlights the importance of collaborations to accelerate vaccine process development and manufacturing under the constant pressure of emerging diseases and the growing need of global immunizations. We are collaborating with the Jenner Institute of the University of Oxford to advance the development of a rapid, scalable and GMP compliant process for simian adenoviruses used as vector for vaccines such as Rabies and emerging threats like Zika and Ebola. This webinar will describe the transition from a labor and time intensive process development to one utilizing a maximum of disposable technologies such as single use bioreactors and filtration technologies, using the rabies vaccine as a first candidate. We will highlight the challenges and their corresponding solutions that in the end created a template that can be used for different types of adenoviral vectors-based vaccines manufacturing. In this webinar, you will learn: - The challenges of creating a rapid and scalable process for Adenovirus vector manufacturing. - The solutions that overcame those challenges. - How public-private collaborations can accelerate vaccine process development.

EpiVax FastVax 23Feb2010

Annie De Groot

HIV Vaccines

Pamoja

Developing a Scalable Upstream Bioreactor Process for Lentiviral Vector Produ...

Merck Life Sciences

Watch the presentation of this webinar here: https://bit.ly/3b3Jc77 Gene therapies hold the promise to change lives. As your path to patients accelerates, how can you assure the robust process design, intensification and scalability that meets your evolving manufacturing needs? What benefits can a templated process bring to your commercial success? As gene therapy progresses toward broader clinical and commercial success, the industry is shifting from treating rare conditions to those of larger populations. This requires scalable solutions for process intensification. In this webinar, we’ll discuss scale-up development for a common viral vector in gene therapy, lentivirus, using the VirusExpress™ Lentiviral Production Platform in Mobius® single-use bioreactors. We will highlight critical considerations when moving from bench-scale to clinical scale process design with manufacturability in mind to ensure commercial readiness. Finally, we’ll review the significant benefits of implementing a templated manufacturing process. In this webinar you will learn: • Scale-up development of a suspension-based lentivirus production process • Designing a process that is manufacturing-friendly and supports commercialization • The benefits of having a templated manufacturing process

Corona vaccines

MAGESHWARSINGH

Cold chain

utpal sharma

Immunization and Cold ChainLivson Thomas

Cold Chain Packing ® Case Study

Nabil Awan

Fresh Fruits & Vegitabales from from Navadhane-Global Agro commodity & Food P...

Karthikeyan Dhanushkodi

Value-added Cold Chain

Asian Food Regulation Information Service

Blockchain technology amplify your enterprise / IBM

COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patients…” by IBM

Recommended

Recommended

More Related Content

What's hot

What's hot (16)

Viewers also liked

Viewers also liked (15)

Similar to COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patients…” by IBM

Similar to COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patients…” by IBM (20)

More from Diego Alberto Tamayo

More from Diego Alberto Tamayo (20)

Recently uploaded

Recently uploaded (20)

COLDCHAIN“Bringing high-quality vaccines and refrigerated medicine to patients…” by IBM